Biologic therapy for inflammatory bowel disease comes of age

Current Gastroenterology Reports

Volumn 9, Issue 6, 2007, Pages 485-488

  Hanauer, Stephen B ^a  

^a NONE

Author keywords

Adalimumab; Adalimumab Group; Biologic Therapy; Certolizumab Pegol; Tumor Necrosis Factor Antagonist

Indexed keywords

EID: 77954008786     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-007-0064-6     Document Type: Article

References (23)

1. Clark M, Colombel JF, Feagan BC, et al.: American Gastroenterological Association Consensus Development Conference on the use of biologics in the treatment of inflammatory bowel disease, June 21–23, 2006. Gastroenterology 2007, 133:312–339. DOI: 10.1053/j.gastro.2007.05.006
2. Sidiorpoulos PI, Boumpas DT: Differential drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 2006, 65:701–703. DOI: 10.1136/ard.2005.049890
3. Sandborn WJ, Hanauer SB, Rutgeerts PJ, et al.: Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut 2007, 56:1232–1239. DOI: 10.1136/gut.2006.106781
4. Colombel JF, Sandborn WJ, Rutgeerts P, et al.: Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007, 132:52–65. DOI: 10.1053/j.gastro.2006.11.041
5. Hanauer SB, Sandborn WJ, Rutgeerts P, et al.: Human antitumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006, 130:323–333, quiz 591. DOI: 10.1053/j.gastro.2005.11.030
6. Rutgeerts P, Van Assche G, Vermeire S: Review article: infliximab therapy for inflammatory bowel disease—seven years on. Aliment Pharmacol Ther 2006, 23:451–463. DOI: 10.1111/j.1365-2036.2006.02786.x
7. Hanauer SB, Feagan BG, Lichtenstein GR, et al.: Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002, 359:1541–1549. DOI: 10.1016/S0140-6736(02)08512-4
8. Hanauer SB, Wagner CL, Bala M, et al.: Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol 2004, 2:542–553. DOI: 10.1016/S1542-3565(04)00238-1
9. Rutgeerts P, Van Assche G, Vermeire S: Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004, 126:1593–1610. DOI: 10.1053/j.gastro.2004.02.070
10. Sandborn WJ: Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease. Curr Gastroenterol Rep 2003, 5:501–505. DOI: 10.1007/s11894-003-0040-8
11. Sandborn WJ, Feagan BG, Stoinov S, et al.: Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med 2007, 357:228–238. DOI: 10.1056/NEJMoa067594
12. Sands BE, Anderson FH, Bernstein CN, et al.: Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004, 350:876–885. DOI: 10.1056/NEJMoa030815
13. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al.: Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med 2007, 357:239–250. DOI: 10.1056/NEJMoa062897
14. Mackey AC, Green L, Liang LC, et al.: Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007, 44:265–267.
15. Rosh JR, Oliva-Hemker M: Infliximab use and hepatosplenic T cell lymphoma: questions to be asked and lessons learned. J Pediatr Gastroenterol Nutr 2007, 44:165–167. DOI: 10.1097/MPG.0b013e318031d61a
16. Van Assche G, Paintaud G, D’Haens G, et al.: Continuation of immunosuppression is not required to maintain adequate infliximab efficacy in patients with Crohn’s disease but may improve pharmacokinetics. Gastroenterology 2006, 130:A142.
17. Rutgeerts P, Diamond RH, Bala M, et al.: Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest Endosc 2006, 63:433–442, quiz 464. DOI: 10.1016/j.gie.2005.08.011
18. Baert F, De Vos M, Louis E, Vermeire S: Immunogenicity of infliximab: how to handle the problem? Acta Gastroenterol Belg 2007, 70:163–170.
19. D’Haens G, Hommes D, Baert F, et al.: A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn’s disease. Gastroenterology 2006, 130:A110.
20. Lemann M, Mary JY, Duclos B, et al.: Infixmab plus azathioprine for steroid-dependent Crohn’s disease patients: a randomized placebo-controlled trial. Gastroenterology 2006, 130:1054–1061. DOI: 10.1053/j.gastro.2006.02.014
21. Hanauer SB: Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Gut 2007, 56:1181–1183. DOI: 10.1136/gut.2006.115980
22. Candy S, Wright J, Gerber M, et al.: A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut 1995, 37:674–678. DOI: 10.1136/gut.37.5.674
23. Markowitz J, Grancher K, Kohn N, et al.: A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology 2000, 119:895–902. DOI: 10.1053/gast.2000.18144